Algorithm for management of patients with pain due to DSPN

Slides:

Advertisements

Similar presentations

GENERALIZED ANXIETY DISORDER IN PRIMARY CARE Curley Bonds, MD Medical Director Didi Hirsch Mental Health Services Professor & Chair Charles R. Drew University.

Advertisements

Pregabalin Efficacy in Peripheral Neuropathic Pain Results from the first 15 months of an ongoing open-label study in patients with treatment-

Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Duloxetine on Pain, Function, and Quality.

Copyright © 2015 by the American Osteopathic Association.

Source: Reprinted with permission from the American Association of Clinical Endocrinologists. Garber AJ, Abraham-son, MJ, Barzilay JI, et al. AACE comprehensive.

(Copyright © 1977 American Diabetes Association. Marliss EB et al

Figure 2 Cumulative proportion of patients experiencing a seizure recurrence after randomization, comparing immediate vs deferred treatment Cumulative.

Volume 70, Issue 8, Pages (October 2006)

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Duloxetine Flavio Guzman, MD.

Current Therapy for Type II Diabetes

Framework for understanding obesity in children and youth.

Rank-order bar chart of percentage of patient-days with blood glucose results > 299 mg/dl for non-ICU units. Rank-order bar chart of percentage of patient-days.

Endothelial Dysfunction in Patients With Lone AF and AF Patients With Comorbidities Compared With That in Controls Comparisons are shown among control.

George Dailey, MD Mayo Clinic Proceedings

Summary of DURATION development program select efficacy results: absolute difference in change in A1C, body weight, systolic blood pressure, and LDL cholesterol.

Figure 6 Pharmacodynamic profile of switching between clopidogrel and ticagrelor therapy: results from the RESPOND study Figure 6| Pharmacodynamic profile.

Insulin and glucagon secretion: nondiabetic and diabetic subjects.

Depiction of the elements of decision making used to determine appropriate efforts to achieve glycemic targets. Depiction of the elements of decision making.

Continuous glucose monitoring tracings of two patients with type 1 diabetes (one patient per panel) on a day when aerobic exercise was performed (open.

Short-Bowel Syndrome Clinical Gastroenterology and Hepatology

Details and Difficulties Regarding the New Lung Cancer Staging System

PWD confidence with key diabetes management activities.

PWD who regularly or occasionally engaged in activities to manage their diabetes. PWD who regularly or occasionally engaged in activities to manage their.

Management of Adult Patients with Hyperosmolar Hyperglycemic Syndrome

The additive model assumes unspecific effects of equal size in both the placebo and drug arm or groups of studies or experiments. The additive model assumes.

Figure 2 Dzyaloshinskii–Moriya interactions

Adapted with permission from Tesfaye, S. , Boulton, A. J

Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Cumulative incidence of diabetes for participants in the Diabetes Prevention Program. Cumulative incidence of diabetes for participants in the Diabetes.

Scatterplot showing the association between baseline weight and weight change at 1 year, relative to baseline for each treatment group. Scatterplot showing.

Figure 1 Timeline of pancreatic islet transplantation

The Clinical Implications of Cytochrome P450 Interactions With Opioids and Strategies for Pain Management Michael J. Brennan, MD Journal of Pain and.

Overview of the actions of SGLT2, including the role of SGLT2 in glucose reabsorption in the proximal tubule (A) and sites of action at which SGLT2 inhibitors.

One- to two-hour plasma glucose concentrations over a 24-hour period in patients taking maximal doses of either glyburide (20 mg/day) or glipizide (40.

The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

An algorithm depicting the basic approach to the Charcot foot

Percentage of Florida adults with diagnosed diabetes who received services or engaged in self-management practices by DSME duration category, Florida BRFSS.

Mean LOS and 30-day all-cause readmission rates before and after conversion to the Interdisciplinary Diabetes Care model. Mean LOS and 30-day all-cause.

Twenty-four–hour glycemic profiles in type 2 diabetic patients under sedentary conditions and under conditions in which prolonged sedentary time was reduced.

Average glucose concentrations over time in people with type 2 diabetes (n = 60; average 24-hour glucose concentration 171 ± 5 mg/dL) and healthy, normoglycemic,

Clustering of fat mass loss profiles in obese subjects and relation with scWAT fibrosis. Clustering of fat mass loss profiles in obese subjects and relation.

Health profile used in workshops to help people make diabetes management decisions. Health profile used in workshops to help people make diabetes management.

Uptake of [11C]5-HTP in the human pancreas is not dependent on perfusion. Uptake of [11C]5-HTP in the human pancreas is not dependent on perfusion. A:

Figure 5 Algorithm for the management of hypertension

PTH response to the predialysis serum calcium concentration in hemodialysis patients with severe (A), moderate (B), and mild (C) hyperparathyroidism. PTH.

This figure illustrates the importance of heart failure consideration in primary endpoint trials with hypoglycemic agents. This figure illustrates the.

Treatment response patterns and effect size over time in exclusively placebo-controlled trials. Treatment response patterns and effect size over time in.

Relationship between week 24 A1C and week 24 BeAM in the exploratory analysis (A), the main analysis (only patients with A1C >7.0% at week 24 were included.

A total of 173 individuals were positive for GADA, and 16 of these were positive for a second antibody (11 were IA-2A positive, and 6 were ZnT8A positive).

ORs of receiving metformin for outcome measures, including age, number of comorbidities, provider age, A1C level, history of CHF, and use of medications,

Protocol for Management of Adult Patients with Diabetic Ketoacidosis

Number of antihypertensive agents prescribed for known nephropaths in phases I and II (▪), with blood pressure recordings falling outside guidelines, compared.

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

A1C at baseline and each maintenance month by treatment in the GEMINI trial, including the modified intention-to-treat population. A1C at baseline and.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Low-volume HIIT leads to rapid improvements in glucose control in individuals with type 2 diabetes. Low-volume HIIT leads to rapid improvements in glucose.

The Primary Care Amplification Model.

Effects of placebo or carvedilol CR on 24-hour mean systolic blood pressure and diastolic blood pressure obtained by ambulatory monitoring in hypertensive.

New dialysis starts in the United States by year in patients with and without diagnosis of diabetes. New dialysis starts in the United States by year in.

Pathway to initial antihypertensive therapy in patients with diabetes

Antihyperglycemic therapy in adults with type 2 diabetes

An insulin simplification regimen: from multiple injections to once-daily long-acting (basal) insulin plus noninsulin agents. *Basal insulins: glargine.

Plasma concentration-time profile after oral administration of a single dose. Plasma concentration-time profile after oral administration of a single dose.

Risk of mortality in patients with diabetes and ESRD

Algorithm for management of the patient with pain because of DSPN

(A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects. (A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects.

Benchmarking scatterplot for non-ICU units.

Presentation transcript:

Algorithm for management of patients with pain due to DSPN Algorithm for management of patients with pain due to DSPN. *Pregabalin is FDA-approved for painful DSPN, whereas gabapentin is not. Algorithm for management of patients with pain due to DSPN. *Pregabalin is FDA-approved for painful DSPN, whereas gabapentin is not. Pharmacokinetic profile, spectrum of AEs and drug interactions, comorbidities, and costs should be considered in selecting the agent of choice. **Duloxetine is FDA-approved for painful DSPN, whereas venlafaxine is not. Pharmacokinetic profile, spectrum of AEs, drug interactions, comorbidities, and costs should be considered in selecting the agent of choice. #None is FDA-approved for painful DSPN. Spectrum of AEs, drug interactions, and comorbidities should be considered in selecting these agents. Reprinted with permission from ref. 1. Lynn Ang et al. Diabetes Spectr 2018;31:224-233 ©2018 by American Diabetes Association